TB Alliance and Partners Form Multidisciplinary Center for Translational TB Drug Research
NEW YORK, NY (May 9, 2019)—The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a Center
NEW YORK, NY (May 9, 2019)—The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a Center
Joint Statement for Multi-stakeholder Hearing on UHC: Product Development Partnerships “We face a collective challenge in ensuring that everyone—regardless where
We spoke with Karl Hofmann, president and CEO of Population Services International (PSI), to hear about his time serving as
NEW YORK, HERTFORDSHIRE, England and PITTSBURGH – April 18, 2019 – Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan
March 20, 2019 – Building a Tuberculosis Free World: The Lancet Commission on Tuberculosis, released today, outlines what is needed
NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has
NEW YORK (February 5, 2019) – TB Alliance applauds the Wellcome Trust’s commitment of over £10 million to the Drugs
Please note: this article discusses a major plot point of Red Dead Redemption 2 For players of Red Dead Redemption
NEW YORK (January 15, 2019)—TB Alliance, a not-for-profit organization dedicated to developing new drug regimens to fight tuberculosis (TB), has
December 4, 2018 – NEW YORK – Though global funding for tuberculosis (TB) research is beginning to move in the